Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Thymoglobulin in Cadaver Donor
- Conditions
- Interventions
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2013-09-11
- Target Recruit Count
- 20
- Registration Number
- NCT01939171
- Locations
- 🇵🇹
Hospital Santa Maria, Lisbon, Portugal
🇪🇸Hospital Universitario La Paz, Madrid, Spain
ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 412
- Registration Number
- NCT01883180
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Non-Myeloablative Conditioning and Bone Marrow Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01850108
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇫🇷Saint-Louis Hospital, Paris, France
🇬🇧St Mary's Hospital, London, United Kingdom
Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 320
- Registration Number
- NCT01844635
- Locations
- 🇯🇵
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 270
- Registration Number
- NCT01810588
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Azienda Ospedaliera San Giovanni Battista
- Target Recruit Count
- 42
- Registration Number
- NCT01786018
- Locations
- 🇮🇹
Città della Salute e della Scienza di Torino, Torino, Italy
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 2
- Registration Number
- NCT01745913
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Belatacept Early Steroid Withdrawal Trial
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 316
- Registration Number
- NCT01729494
- Locations
- 🇺🇸
University of Wisconsin-Madison, Madison, Wisconsin, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 6
- Registration Number
- NCT01622556
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 100
- Registration Number
- NCT01499147
- Locations
- 🇺🇸
University of Illinois at Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.